These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7109939)

  • 1. [Hepatotoxicity of the tuberculostatic combination INH+RMP+EMB in relation to drug metabolism in the liver].
    Musch E; Eichelbaum M; Wang JK; von Sassen W; Ochs HR; Castro-Parra M; Dengler HJ
    Med Welt; 1982 Jun; 33(25):911-4. PubMed ID: 7109939
    [No Abstract]   [Full Text] [Related]  

  • 2. [The adverse effects of 2 therapy combinations (SM, PAS, INH, RMP, INH, EMB) in the intensive treatment phase of pulmonary tuberculosis].
    Knop P; Kindler U; Merholz T
    Med Welt; 1976 Feb; 27(8):389-90. PubMed ID: 1256308
    [No Abstract]   [Full Text] [Related]  

  • 3. [RMP and INH plasma levels in comparison to aminotransferase behavior during a tuberculostatic threefold combination therapy].
    Knop P; Kindler U; Austerhoff A
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1593-6. PubMed ID: 347790
    [No Abstract]   [Full Text] [Related]  

  • 4. [New findings concerning the biochemical mechanisms of the tuberculous process and the correction of biochemical abnormalities using etiopathogenetic preparations].
    Maliuk VI
    Probl Tuberk; 1984 Nov; (11):61-4. PubMed ID: 6395132
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
    Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 8. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
    Musch E; Eichelbaum M; Wang JK; von Sassen W; Castro-Parra M; Dengler HJ
    Klin Wochenschr; 1982 May; 60(10):513-9. PubMed ID: 7098379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute liver failure caused by isoniazid in a child receiving carbamazepine.
    Berkowitz FE; Henderson SL; Fajman N; Schoen B; Naughton M
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):603-6. PubMed ID: 9661830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid-rifampicin induced lipid changes in rats.
    Pal R; Rana SV; Vaiphei K; Singh K
    Clin Chim Acta; 2008 Mar; 389(1-2):55-60. PubMed ID: 18157944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fulminant hepatic failure due to tuberculostatic drugs: case report].
    Malla I; Fauda M; Casanueva E; Fernández MI; Amante M; Cheang Y; Giacove G; Pedreira A; Petracca P; González Campaña A; Silva M; Podestá G
    Arch Argent Pediatr; 2012; 110(3):e35-8. PubMed ID: 22760756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid hepatotoxicity among drug users: the role of hepatitis C.
    Fernández-Villar A; Sopeña B; Vázquez R; Ulloa F; Fluiters E; Mosteiro M; Martínez-Vázquez C; Piñeiro L
    Clin Infect Dis; 2003 Feb; 36(3):293-8. PubMed ID: 12539070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis].
    Kobashi Y; Okimoto N; Matsushima T; Abe T; Nishimura K; Shishido S; Kawahara S; Shigeto E; Takeyama H; Kuraoka T
    Kekkaku; 2000 Dec; 75(12):699-704. PubMed ID: 11201137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.
    Ekochin LH; Manadan AM; Aggarwal R; Sequeira W; Block JA
    J Rheumatol; 2009 Sep; 36(9):2127. PubMed ID: 19738229
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fulminant hepatitis during the therapy for tuberculous meningitis].
    Garavelli PL
    Recenti Prog Med; 1996 Dec; 87(12):597. PubMed ID: 9102699
    [No Abstract]   [Full Text] [Related]  

  • 17. [Case of fatal liver failure due to anti-tuberculous therapy].
    Harada Y; Kawakami K; Koyama K; Yamaryo T; Kimura Y
    Kekkaku; 2007 Sep; 82(9):705-9. PubMed ID: 17969987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of reduced bioavailability of rifampicin.
    Joshi SR
    J Assoc Physicians India; 1999 Sep; 47(9):943-4. PubMed ID: 10778683
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
    Singh J; Garg PK; Thakur VS; Tandon RK
    Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynaecomastia during antituberculosis chemotherapy with isoniazid.
    Dixit R; Sharma S; Nawal CL
    J Assoc Physicians India; 2008 May; 56():390-1. PubMed ID: 18700651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.